Building the backbone of Psychedelic-Assisted Care (PAC) in the U.S.
The Mental Health Crisis Needs a New Infrastructure
Psychedelic-Assisted Care (PAC) is moving from fringe to frontline in treating trauma, depression, addiction, and end-of-life distress. But as legalization spreads, providers are missing one thing: infrastructure. No banking. No merchant services. No insurance. We’re fixing that.
NPA Services is building the essential services layer for this new field. We have already delivered banking, payroll, compliance, and practice management tools to this unique market. Next we’re focused on building a high-margin, high-demand, PAC-tailored captive insurance offering.
Our Current Progress
We support over 62% of licensed clinics in Oregon, the first legal PAC state.
- 13 / 21 licensed clinics in Oregon are already paying members
- Merchant services, banking, regulatory support, and proprietary tech platform all live
Facilitator and manufacturer services launching next
“The NPA actually made it possible for us to have banking and merchant services. That’s been key to our success.”
The Bottleneck = Insurance
The #1 pain point in this market is insurance. Today, PAC providers report premiums of $12K–$26K annually (if they can find policies at all). Most operate uninsured or with inappropriate coverage. The expensive policies available are not even designed for regulated psychedelic operators.
We’re launching first-of-its-kind, fit-for-purpose liability insurance through an association captive model purpose-built for PAC.
- 112 signed letters of intent (LOI) for coverage (51 clinics, 61 facilitators), equating to $750K in year-one demand already
- Actuarial work underway with Oliver Wyman
- Premiums to be offered by NPA are projected to be 30–35% below alternatives
- Targeting 30 – 40% gross margins
“When the NPA offers general liability and malpractice coverage, it will be a game-changer.”
Market Potential
| Phase | Clinics | Facilitators | Est. Annual Premiums |
|---|---|---|---|
| Current (OR, CO, NM) | 100+ | 750+ | $1.5M+ |
| Mid-Term (10 states) | 750+ | 6,000+ | $10M+ |
| Long-Term (Nationwide) | 3,000+ | 25,000+ | $50M+ |
This is sticky, recurring revenue with high retention and strong cross-sell to future NPA services.
Funding Ask
We are currently raising our bridge round, to complete an actuarial study for our captive insurance products for the PAC market, to formalize business operations, and secure additional, fractional resources.
- $750K to seed the captive insurance entity (10% already committed)
- $3.5M Series A to scale operations and expand nationally
Bridge investors invited now at:
- $6M cap, 80% discount to Series A
Why the NPA
- First-mover: Only provider offering end-to-end infrastructure and wraparound services for PAC
- Traction: Existing, paying members (necessary for a captive proposition), LOI-validated sales pipeline, and proven market demand
- Moat: Captive insurance is hard to replicate and deepens member loyalty
- Advocacy wins: NPA’s work in the courts has resulted in the DEA considering moving psilocybin to Schedule II, helping move this sector not just from fringe to front-line, but also gaining federal recognition
- Expertise: Team in place with legal, insurance, tech, and healthcare experience
Let’s Talk
We’re building the rails for a transformative new healthcare category. The time to lead this market is now.
Please get in touch with Mathew Grimes, our Insurance Lead, to discuss this investment opportunity in more detail. Use the contact details below, or book a time that suits you, directly with him, via Calendly, also below.
Thank you for your interest, we look forward to talking with you.
Non-solicitation, legal footnote
This information has been prepared solely for informational purposes in connection with a potential private placement of securities by NPA Services Inc., a Delaware corporation (the “Company”) and is strictly confidential. By accepting and accessing this document, you agree that you will not copy, distribute, or disclose any of its contents to any third party without the prior written consent of the Company. These materials do not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. Any offering of securities will be made only pursuant to definitive offering documents provided by the Company, including a private placement memorandum and subscription agreement.
The securities described herein have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any U.S. state “Blue Sky” laws, and are being offered in reliance on an exemption from registration pursuant to Rule 506 of Regulation D under the Securities Act. Accordingly, these securities are “restricted securities” and may not be resold or transferred without compliance with applicable federal and state securities laws. Neither the U.S. Securities and Exchange Commission nor any state securities regulator has passed upon the merits of this offering or the adequacy of these materials. Any representation to the contrary is unlawful.
This offering is intended solely for “accredited investors,” as defined in Rule 501(a) of Regulation D. Investors will be required to verify accredited status prior to any investment. No securities are being offered or sold to any person who is not an accredited investor. The Company will take steps to comply with Blue Sky filing requirements in all applicable U.S. states and territories; however, no offer or sale will be made except in compliance with the securities laws of the relevant jurisdiction.
These materials contain forward-looking statements that involve substantial risks and uncertainties. Actual results may differ materially from those expressed or implied in such statements due to a variety of factors, including market conditions, regulatory developments, and the Company’s execution capabilities. Forward-looking statements speak only as of the date these materials were prepared and presented. The Company expressly disclaims any obligation to update or revise any such statements.
Investing in the securities described involves a high degree of risk, including the risk of total loss of investment, and should be undertaken only by persons who can afford such loss and lack of liquidity. These securities are illiquid and no public market currently exists or is expected to develop.
This summary is not intended to be complete and does not contain all information necessary to make an investment decision. Nothing herein constitutes investment, legal, tax, or accounting advice. Each prospective investor should conduct their own independent due diligence and consult their own professional advisors.
